Rheumatoid Arthritis eJournal Club
   

Failing a TNF Inhibitor: What About Switching?

Print this Content
 
Release Date:  February 24, 2009 Renewal Date:  March 1, 2010 Expiration Date:  September 1, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion

1 hour

Description / Overview

The purpose of this activity is to discuss treatment options for a patient with rheumatoid arthritis (RA) who has had an inadequate response to treatment with a tumor necrosis factor (TNF) inhibitor.
Objectives On completion of this activity, participants should be able to:
  1. Discuss reported response when switching between TNF inhibitors or to another biologic disease-modifying antirheumatic drug (DMARD) with another mechanism of action.
  2. Describe why a patient with RA may have an inadequate response to a biologic DMARD.
  3. Assess treatment options for a patient with RA when it is determined that therapy with one biologic DMARD is no longer beneficial.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty Yusuf Yazici, MD
Assistant Professor of Medicine
New York University School of Medicine
NYU Hospital for Joint Diseases
New York, New York
Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Leonard H. Calabrese, DO
  Consulting: Abbott Laboratories; Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.
 
Yusif Yazici, MD
  Consulting: Bristol-Myers Squibb Company; Centocor, Inc.; Genentech, Inc.; Roche Laboratories, Inc.; UCB
 
  Teaching and Speaking: Bristol-Myers Squibb Company; Pfizer Inc

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

Bristol – Myers Squibb Company, Genentech/Biogen Idec

Wyeth Pharmaceuticals

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME.

CME Disclaimer